5 patents currently held
17 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2038. from the record
Of the 17 now held by other companies, 15 name Université Paris Cité as their current owner, and 2 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2038
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Feb 2038 · High confidence
Also notable
Ends Sep 2039 · High confidence
Method for Generating T Cells Progenitors
US 11,426,430
A family of 6 related applications built on the 2022 grant. Protection runs to 2038.
Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy
US 12,778,952
Granted 2026. Too new for citation comparison; protection runs to 2039.
Formerly held, still cited
Notable
Ends Oct 2035 · Medium confidence
The most cited patent in this portfolio, cited by 8 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2035.
now held by Université Paris Cité
Also notable
Ends Dec 2035 · High confidence
The earliest of the three still in force, granted 2019 and renewed since. Its term ends first, in 2035.
now held by Université Paris Cité
Also notable
Ends Jun 2032 · Medium confidence
Granted 2023. Computed term ends 2032. A terminal disclaimer caps this term to an earlier patent's.
now held by Université Paris Cité
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods for Inducing Full Ablation of Hematopoiesis | 1 in force | to May 2043 |
| Recombinant Vectors Suitable for the Treatment of Ipex Syndrome | 1 in force | to Dec 2042 |
| Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy | 1 in force | to Sep 2039 |
| Methods and Pharmaceutical Compositions for the Treatment of FGFR3-RELATED Chondrodysplasias | 1 in force | to Jan 2039 |
| Method for Generating T Cells Progenitors | 1 in force | to Feb 2038 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
Also on record, not counted in the 5: 17 patents in force now held by others · 5 patents ended · 41 applications pending · 28 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 patents carry no fee events. That is a gap in the record, not evidence of lapse, so status falls back to the computed term